Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy ...

Rani Therapeutics stock surged 200% after securing a $1 billion partnership with Chugai and raising $60 million in funding.

Novo Nordisk NVO has moved to convene an Extraordinary General Meeting (EGM) after a rare and public disagreement over board ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

As GLP-1 weight-loss drugs like Ozempic reshape how consumers eat, food and beverage manufacturers are racing to develop ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is increasing in clinical trials to treat overlapping ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – ...